A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
Recruiting · NCT07728383 · Interventional (participants receive a specific treatment) · Lead sponsor: Gila Therapeutics, Inc.
View the official record on ClinicalTrials.gov →Interventions studied
Placebo liquid emulsion formulationSemaglutide 6 mg liquid emulsion formulationWegovy® (semaglutide) Tablet
What this trial is about
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Body Mass Index 30 to 45
Exclusion criteria
- Type 2 Diabetes Mellitus
- Multiple Endocrine Neoplasia Type 2
- Medullary thyroid cancer
Where it is running
1 location listed across 1 US state.
- Clinical Research Institute of Minnesota - Minneapolis, Minnesota, United States